These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11439888)

  • 1. [Etiological mechanism of long QT syndrome and the effects of macrolides].
    Kato T
    Jpn J Antibiot; 2001 Feb; 54 Suppl A():118-22. PubMed ID: 11439888
    [No Abstract]   [Full Text] [Related]  

  • 2. Congenital and acquired long QT syndrome.
    Camm AJ; Janse MJ; Roden DM; Rosen MR; Cinca J; Cobbe SM
    Eur Heart J; 2000 Aug; 21(15):1232-7. PubMed ID: 10924312
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome.
    Van Langen IM; Birnie E; Alders M; Jongbloed RJ; Le Marec H; Wilde AA
    J Med Genet; 2003 Feb; 40(2):141-5. PubMed ID: 12566525
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic background predisposing the drug-induced long QT syndrome].
    Horie M
    Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):401-7. PubMed ID: 12835534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ion channels. A new wave for heart rhythms.
    Attali B
    Nature; 1996 Nov; 384(6604):24-5. PubMed ID: 8900269
    [No Abstract]   [Full Text] [Related]  

  • 6. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.
    Yang P; Kanki H; Drolet B; Yang T; Wei J; Viswanathan PC; Hohnloser SH; Shimizu W; Schwartz PJ; Stanton M; Murray KT; Norris K; George AL; Roden DM
    Circulation; 2002 Apr; 105(16):1943-8. PubMed ID: 11997281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
    Berthet M; Denjoy I; Donger C; Demay L; Hammoude H; Klug D; Schulze-Bahr E; Richard P; Funke H; Schwartz K; Coumel P; Hainque B; Guicheney P
    Circulation; 1999 Mar; 99(11):1464-70. PubMed ID: 10086971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
    Vincent GM
    Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac arrhythmias: the genetic connection.
    Towbin JA
    J Cardiovasc Electrophysiol; 2000 May; 11(5):601-2. PubMed ID: 10826942
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutation detection in long QT syndrome: a comprehensive set of primers and PCR conditions.
    Syrris P; Murray A; Carter ND; McKenna WM; Jeffery S
    J Med Genet; 2001 Oct; 38(10):705-10. PubMed ID: 11594341
    [No Abstract]   [Full Text] [Related]  

  • 12. KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population.
    Liu W; Yang J; Hu D; Kang C; Li C; Zhang S; Li P; Chen Z; Qin X; Ying K; Li Y; Li Y; Li Z; Cheng X; Li L; Qi Y; Chen S; Wang Q
    Hum Mutat; 2002 Dec; 20(6):475-6. PubMed ID: 12442276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
    Pearlstein R; Vaz R; Rampe D
    J Med Chem; 2003 May; 46(11):2017-22. PubMed ID: 12747773
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel KCNQ1 and HERG missense mutations in Dutch long-QT families.
    Jongbloed RJ; Wilde AA; Geelen JL; Doevendans P; Schaap C; Van Langen I; van Tintelen JP; Cobben JM; Beaufort-Krol GC; Geraedts JP; Smeets HJ
    Hum Mutat; 1999; 13(4):301-10. PubMed ID: 10220144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology.
    Roden DM; Balser JR
    Cardiovasc Res; 1999 Nov; 44(2):242-6. PubMed ID: 10690299
    [No Abstract]   [Full Text] [Related]  

  • 16. The long QT syndromes: genetic basis and clinical implications.
    Chiang CE; Roden DM
    J Am Coll Cardiol; 2000 Jul; 36(1):1-12. PubMed ID: 10898405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
    Volberg WA; Koci BJ; Su W; Lin J; Zhou J
    J Pharmacol Exp Ther; 2002 Jul; 302(1):320-7. PubMed ID: 12065733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cardiac safety of ebastine. Epilogue.
    Roberts DJ
    Drug Saf; 1999; 21 Suppl 1():89-92. PubMed ID: 10597871
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
    Antzelevitch C
    J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long QT syndrome: more questions.
    Moss AJ
    J Cardiovasc Electrophysiol; 2001 Apr; 12(4):462. PubMed ID: 11332569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.